Exact Sciences
In Brief This Week: Count Me In, VolitionRx, CareDx, Centogene, Golden Helix, TeleRare Health, More
News items for the week of March 10, 2025
Exact Sciences Solidifies MRD and Multi-Cancer Screening Plans as Q4 Revenues Rise 10 Percent
Premium
Growth was mainly driven by an increase in colorectal cancer screening revenue, while precision oncology testing income was flat year over year.
Flatiron Health, Exact Sciences Partner on Study of Molecular Residual Disease Test
The collaborators have enrolled their first patient in a prospective clinical study testing a tumor-informed assay for monitoring recurrence across multiple cancers.
Barclays Initiates Coverage of Guardant Health, Exact Sciences, Natera With Overweight Rating
The investment firm cited large, unpenetrated markets for liquid biopsy in residual disease detection, monitoring, and screening.
JP Morgan Healthcare Conference, Day 1: Oxford Nanopore, 10x Genomics, Bruker, Qiagen, More
Highlights from the first day included Exact Sciences' plan to launch three new cancer tests in 2025 and Qiagen's sample prep launch plans for 2026.
Oct 29, 2024